

April 4, 2018



## Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference

LYON, France--(BUSINESS WIRE)-- [POXEL SA](#) (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the H.C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10<sup>th</sup> at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

Poxel will present a corporate overview on Tuesday, April 10<sup>th</sup> at 9:50-10:15 AM CEST in Salon Atlantique-Meridional (2nd Floor) and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. To access the webcast, please visit the following link <http://wsw.com/webcast/hcw2/poxel.pa/>. The webcast replay will remain available for 90 days following the live presentation.

### About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., EU and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 TIMES program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences will be responsible for Imeglimin's development and commercialization in countries outside of Poxel's partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. Our second program, PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in Phase 1 and we plan on developing it for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, [www.poxelpharma.com](http://www.poxelpharma.com))

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20180403006260/en/>

### Poxel SA

Jonae R. Barnes, +1 617-818-2985

Senior Vice President, Investor Relations and Public Relations

[jonae.barnes@poxelpharma.com](mailto:jonae.barnes@poxelpharma.com)

or

**Investor relations / Media - EU/US**

Trophic Communications

Gretchen Schweitzer, +49 89 238 877 34

or

Stephanie May, +49 171 185 56 82

[may@trophic.eu](mailto:may@trophic.eu)

or

**Investor relations / Media - France**

NewCap

Alexia Faure/Nicolas Merigeau, +33 1 44 71 98 55

[poxel@newcap.fr](mailto:poxel@newcap.fr)

Source: Poxel SA